Ayuna Jombik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayuna Jombik has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alison Elizabeth Smith
Kura Oncology, Inc., San Diego, California
12 shared publications - Amitava Mitra
Kura Oncology, Inc. San Diego California USA
12 shared publications - Francis Burrows
Kura Oncology, Inc., San Diego, California
12 shared publications - Hetika Vora Patel
Kura Oncology, Inc., San Diego, California
12 shared publications - John Edward Greer
Kura Oncology, Inc., San Diego, California
12 shared publications - Jovylyn Gatchalian Gasendo
Kura Oncology, Inc., San Diego, California
12 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
KO-2806 addition re-sensitizes tumors to KRAS inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
KO-2806 addition re-sensitizes tumors to KRAS inhibition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Pharmacokinetic profile, tolerability, and antitumor efficacy of KO-2806.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Pharmacokinetic profile, tolerability, and antitumor efficacy of KO-2806.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Combination of KO-2806 and adagrasib inhibits mTOR signaling and induces tumor regression in KRASG12C-mutant NSCLC models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Combination of KO-2806 and adagrasib inhibits mTOR signaling and induces tumor regression in KRASG12C-mutant NSCLC models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Comparison of the physiochemical, metabolic, distribution, and pharmacokinetic properties of KO-2806 and the first-generation FTI tipifarnib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Comparison of the physiochemical, metabolic, distribution, and pharmacokinetic properties of KO-2806 and the first-generation FTI tipifarnib.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Instructions for synthesis of KO-2806
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Instructions for synthesis of KO-2806
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Antitumor efficacy and tolerability of combined adagrasib and KO-2806 in KRASG12C-mutant NSCLC xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Antitumor efficacy and tolerability of combined adagrasib and KO-2806 in KRASG12C-mutant NSCLC xenograft models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Antitumor efficacy and tolerability of combined KO-2806 and MRTX1133 or RMC-6236 in KRAS-mutant CRC xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Antitumor efficacy and tolerability of combined KO-2806 and MRTX1133 or RMC-6236 in KRAS-mutant CRC xenograft models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
The combination of KO-2806 and mutant-selective KRAS or pan-RAS inhibitors inhibits mTOR signaling in CRC models and is tolerable in vivo
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
The combination of KO-2806 and mutant-selective KRAS or pan-RAS inhibitors inhibits mTOR signaling in CRC models and is tolerable in vivo
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Resistance remains a key issue limiting the clinical benefit from RAS-targeting therapeutic agents and necessitates combination approaches. In this study, we identified persistent mTORC1 activity in preclinical KRAS-mutant non–small cell lung cancer (NSCLC) and colorectal cancer models as a frequent, nongenetic driver of inherent and adaptive resistance to RAS inhibition. This vulnerability was targetable with the farnesyl transferase inhibitor darlifarnib (KO-2806), which blocks mTORC1 activation via RHEB while sparing mTORC2 to limit associated toxicities. The addition of KO-2806 to NSCLC or colorectal cancer tumors progressing on mutant-selective RAS inhibitors led to rapid and durable tumor regression. In contrast, switching from mutant-selective to pan-RAS inhibitor monotherapy resulted in only stasis of NSCLC tumors and had no effect on colorectal cancer tumor progression. Furthermore, the addition of KO-2806 rescued sensitivity of progressing tumors to the pan-RAS inhibitor RMC-6236. These results establish mTORC1 as an important mediator of escape from RAS inhibition and highlight KO-2806 as a promising RAS companion inhibitor in patients with prior RAS inhibitor exposure.Significance:KO-2806 salvages RAS inhibitor activity by controlling parallel mTORC1 in RAS inhibitor-resistant tumors in which vertical inhibition of MAPK is insufficient to restore sensitivity, providing a combination strategy for resistant patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Resistance remains a key issue limiting the clinical benefit from RAS-targeting therapeutic agents and necessitates combination approaches. In this study, we identified persistent mTORC1 activity in preclinical KRAS-mutant non–small cell lung cancer (NSCLC) and colorectal cancer models as a frequent, nongenetic driver of inherent and adaptive resistance to RAS inhibition. This vulnerability was targetable with the farnesyl transferase inhibitor darlifarnib (KO-2806), which blocks mTORC1 activation via RHEB while sparing mTORC2 to limit associated toxicities. The addition of KO-2806 to NSCLC or colorectal cancer tumors progressing on mutant-selective RAS inhibitors led to rapid and durable tumor regression. In contrast, switching from mutant-selective to pan-RAS inhibitor monotherapy resulted in only stasis of NSCLC tumors and had no effect on colorectal cancer tumor progression. Furthermore, the addition of KO-2806 rescued sensitivity of progressing tumors to the pan-RAS inhibitor RMC-6236. These results establish mTORC1 as an important mediator of escape from RAS inhibition and highlight KO-2806 as a promising RAS companion inhibitor in patients with prior RAS inhibitor exposure.Significance:KO-2806 salvages RAS inhibitor activity by controlling parallel mTORC1 in RAS inhibitor-resistant tumors in which vertical inhibition of MAPK is insufficient to restore sensitivity, providing a combination strategy for resistant patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Intermittent dosing of KO-2806 leads to tumor regressions in combination with RAS inhibitors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition
Intermittent dosing of KO-2806 leads to tumor regressions in combination with RAS inhibitors.